Navigation Links
Interesting stories at the IMPAKT Breast Cancer Conference
Date:5/7/2010

Abstract 35P: Markers for risk of pregnancy-associated breast cancer
C.B. Agborsangaya, FINLAND
As women delay child-birth to the third and fourth decades, the incidence of pregnancy-associated breast cancer is expected to rise. This paper suggests that identification of p53 autoantibody-positive pregnant women may be useful in predicting outbreak or early detection of pregnancy-associated breast cancer.

Abstract 92P: Post traumatic stress disorder in breast cancer patients
E. Calbari, GREECE
Having breast cancer is not a merely stressful experience, but rather involves a cascade of unfolding threats and stressors. According to new findings, 45% of patients treated reported cancer-related PTSD and poorer quality of life even after 3 years of diagnosis and treatment.

Abstract 108P: Delivering RNA interference to HER2 overexpressing breast cancer
E. Song, CHINA
Researchers investigated the specificity and efficiency of a fusion protein against HER-2 and truncated protamine to deliver siRNAs into HER-2 expressing breast cancer cells in vitro and in vivo. The proteins can selectively deliver siRNA to HER2 overexpressing breast cancer cells in vitro and in vivo.

Abstract 102P: MicroRNAs regulate the stemness of breast tumor initiating cells
E. Song, CHINA
Researchers show that self-renewal of breast cancer stem cells are tightly regulated by microRNAs, suggesting that targeting delivery of tumor-suppressing microRNAs into breast tumor initiating cells emerges to be a novel approach for breast cancer treatment.

Abstract 27P: A fingerprint potentially correlated with the presence of micro-metastatic disease in early breast cancer
C. Oakman, ITALY,
This pilot study uses serum metabolomic profiles to discriminate between early and advanced breast cancer patients. Compared with traditional risk factors, metabolomics may identify more pts with lower relapse risk. Validation of this model in a cohort of pts with long term follow-up is underway.

Abstract 36P: Assessment of circulating tumor cells (CTCS) in blood of primary invasive duct carcinoma (PIDC) patients
A.A. Bahnassy, EGYPT
Prognosis of breast cancer patients is still limited by the occurrence of distant metastases. 1) Detection and monitoring of CTCs in blood is an easy, non-invasive procedure enabling repeated analyses. 2) Flow-cytometry provides a simple and accurate technique for enumerating CTCs in peripheral blood. 3) The presence of CTCs in the blood of PIDC patients can predict prognosis.

Abstract 72P: Patterns of care in elderly breast cancer patients
A. Mahipal, UNITED STATES OF AMERICA,
Elderly breast cancer (age 65 years or more) patients are underrepresented in most of clinical trials. This study suggests that the proportion of elderly patients receiving chemotherapy is increasing in recent years. Elderly patients who received chemotherapy had better clinical outcomes than those who did not. Age should not be a sole factor in determining chemotherapy administration.

Abstract 142P: New drug candidate? Synthetic analogues of flavaglines
L. Dsaubry, FRANCE
Flavaglines are a family of natural compounds. This study suggests that flavaglines are a novel class of molecules that selectively induce the death of cancer cells independently of the classical apoptosis pathways, and do not display any sign of toxicity in vivo.

Abstract 67P: Gene differences predict survival outcomes after chemotherapy in breast cancer patients
E. Castro Marcos, SPAIN
Single nucleotide polymorphisms SNPs in genes XRCC3 and XRCC1 are associated with different outcomes, likely attributable to the differential abilities to repair anthracycline-induced DNA damage. These promising findings have pharmacogenomics implications in matching particular adjuvant CT for specific cancer patients.

Abstract 140P: New target for breast cancer? The sodium-iodide symporter
N. Fortunati, ITALY,
The sodium-iodide symporter (NIS) mediates iodide uptake into thyroid cells allowing radioiodine imaging and therapy in thyroid cancer. NIS is also expressed in lactating mammary glands, and in more than 80% of human breast carcinomas. This study reports that the pan-deacetylase (DAC) inhibitor LBH589 induces NIS expression and function in breast cancer cultured cells. LBH589 appears to be an interesting compound in the managing of breast cancer, giving the opportunity of using radioiodide as further diagnostic and therapeutic tool.

Abstract 143P: Combination of ASA404 (vadimezan) with paclitaxel and trastuzumab
D.B. Evans, SWITZERLAND
ASA404 is a flavonoid, non tubulin-binding Tumour-Vascular Disrupting Agent that induces breakdown of the established tumor vasculature and hence inhibition of the tumor blood supply, leading to ischemia and extensive necrosis of the tumor core. This study shows that it enhances the activity of trastuzumab and paclitaxel, highlighting the potential value of this combination in breast cancer treatment.

Abstract 105P: Overcoming trastuzumab resistance?
M. Gijsen, UNITED KINGDOM.
It is still poorly understood how trastuzumab exerts its tumor inhibition effect. Its acquired resistance mechanisms are also not yet fully determined. This study provides evidence that trastuzumab resistance can be mediated by activation of HER family ligands as a result of a PKB negative feedback loop. This offers treatment opportunities for overcoming resistance in these patients, including approaches to target all HER receptors in combination with trastuzumab treatment.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. And the Winner is… After Online Vote, Austin Cosmetic Dentist Crowns the Most Interesting Dental Patient in the World
2. 10 Days Left to Win $15,000 in Dental Work for Most Interesting Patient in the World Contest at Austin Cosmetic Dentistry Practice
3. The Top Health Stories Of 2009, From The Harvard Health Letter
4. Phonak Asks Young FM Users to Tell Their Stories on YouTube
5. National Kidney Month 2010: Stories of Hope About the Prevention and Maintenance of Kidney Disease from The Kidney TRUST
6. Upstate Business Tells Stories Through New Media
7. IMPAKT Breast Cancer Conference press program
8. Targeted therapy prolongs life in patients with HER2-positive breast cancer
9. New Drugs, New Combinations Fight Breast Cancer
10. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
11. Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... ... , is pleased to announce a new online course entitled Personal & ... practical insights and evidence-based strategies for achieving optimal well-being and teaches students how ...
(Date:6/20/2017)... ... , ... Kenneth Mayer, MD, has been appointed a new Editor-in-Chief of the ... the JIAS Editorial Board in 2016, has co-authored more than 800 peer-reviewed publications. Among ... and Co-Chair of The Fenway Institute, a member of the US President’s Emergency ...
(Date:6/20/2017)... York, NY (PRWEB) , ... June 20, 2017 , ... ... today their continued expansion and success in the clinical trials market. Similar to its ... a track record in the clinical trials marketplace by proving the value of eVisits ...
(Date:6/20/2017)... ... June 20, 2017 , ... Dr. Manju R. Kejriwal ... leading-edge care, whether or not they have a referral. Dr. Kejriwal offers state-of-the-art ... laser, she targets bacteria and damaged tissue without affecting the surrounding tissue. This ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... (AHN) Jefferson Hospital is providing physicians with advanced capabilities for diagnosing and treating ... than traditional MRIs, enabling doctors to get a more accurate look inside the ...
Breaking Medicine News(10 mins):
(Date:6/13/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... the U.S. Food and Drug Administration (FDA) has notified the ... to its Zhejiang, China manufacturing facility ... "The successful clearance of the Warning Letter related to our ... a measure of the progress we have made in our ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
Breaking Medicine Technology: